Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587142 · ClinicalTrials.gov registry record · Phase 2
Buspirone for Early Satiety and Symptoms of Gastroparesis
A Phase 2 study, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT03587142 is a Phase 2 study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 96 participants.
The verdict
NCT03587142, a Phase 2 study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
This study evaluates whether the study medication, buspirone, an antianxiety drug, improves the symptoms of gastroparesis in patients with gastroparesis symptoms and at least moderately severe symptoms of fullness and/or inability to eat a full meal. Half the patients will receive buspirone and half the patients will receive a placebo.
Interventions
- DRUG Placebo
- DRUG Buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2019-08-27 |
| Est. Completion | 2022-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03587142
The ClinicalTrials.gov registry entry for NCT03587142 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins Bloomberg School of Public Health, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03587142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03587142 about?
NCT03587142 is a clinical study titled "Buspirone for Early Satiety and Symptoms of Gastroparesis". This study evaluates whether the study medication, buspirone, an antianxiety drug, improves the symptoms of gastroparesis in patients with gastroparesis symptoms and at least moderately severe symptoms of fullness and/or inability to eat a full meal. Half the patients will receive buspirone and half...
What is the current status of trial NCT03587142?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2019-08-27. Estimated completion is 2022-04-30.
What interventions are being tested in trial NCT03587142?
The interventions under investigation include: Placebo (DRUG), Buspirone (DRUG).
Who is sponsoring clinical trial NCT03587142?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.